Proposal for SC79 (Sigma-Aldrich catalog #S7944)

Below is a comprehensive evaluation of SC79 as a repurposed therapeutic candidate for Polycystic Ovary Syndrome (PCOS), assembled from multiple lines of evidence in the biomedical, clinical, and biochemical literature provided.

Overview of Therapeutic Candidate:
SC79 is a fully synthetic, small-molecule compound that emerged from high-throughput cell–based screening efforts aimed at identifying modulators of Akt activity. Its discovery was serendipitous when researchers sought compounds that interfered with the normal translocation of Akt to the plasma membrane. Instead of acting as an inhibitor, SC79 was found to bind directly to the pleckstrin homology (PH) domain of Akt; this binding induces a favorable conformational change that promotes its membrane translocation and, consequently, its phosphorylation at key regulatory residues (Thr308 and Ser473). SC79 is classified within the family of allosteric kinase activators—an emerging class of therapeutic compounds that activate kinase enzymes by binding sites distinct from the ATP binding pocket. Unlike traditional inhibitors that compete at the catalytic site, these allosteric agents are designed to “rescue” or potentiate the activity of enzymes when upstream signaling is compromised. This strategy is particularly important in scenarios where defects in receptor signaling or activation of intermediary molecules (such as IRS-1 or PI3K) reduce the natural activation of Akt. The synthetic origins of SC79, along with its relatively straightforward chemical structure (as evidenced by its catalog availability from Sigma-Aldrich, S7944), make it an attractive candidate for repurposing. Preclinical studies have previously leveraged compounds of this class to restore or enhance Akt activity in contexts where Akt-dependent pathways are downregulated, such as in ischemia-induced neuronal injury and cardiomyocyte survival models (Jo et al., 2012; Jing et al., 2019). This class has also proven beneficial in models where downstream components must be activated directly because of defects in upstream insulin receptor signaling—a condition highly relevant to the pathophysiology of PCOS.

Therapeutic History:
SC79 has been studied almost exclusively in preclinical and experimental models rather than in clinical settings. The initial studies focusing on SC79 examined its role in protecting neuronal cells from ischemia-induced death by promoting robust Akt phosphorylation, which translated to increased cell survival and reduced apoptosis in models of stroke and subarachnoid hemorrhage. In addition to neuroprotective effects, SC79 has been investigated in hepatocyte models, where it effectively protected liver cells from TNF-α-mediated apoptosis and mitigated liver injury in Gal/LPS-induced models (Jing et al., 2019). With respect to its broader classification as an Akt activator, similar molecules have been investigated for their ability to bypass defects in upstream insulin signaling. Under conditions where the insulin receptor or insulin receptor substrate (IRS) encounters functional defects, the PI3K/Akt signaling cascade becomes compromised. In disorders such as PCOS, numerous studies have demonstrated that the loss or impairment of IRS-1 phosphorylation—and consequently, decreased PI3K activation—leads to attenuated Akt signaling in relevant tissues including skeletal muscle and ovarian cells (Baptiste et al., 2010; Chakrabarty & Nagamani, 2008). Although SC79 has not been directly tested in ovarian or theca cells derived from PCOS patients, its preclinical history in other cell types and disease models provides compelling indirect evidence for its repurposing. For instance, in models where defective upstream signaling was observed, direct activation of Akt was capable of rescuing downstream metabolic and pro-survival pathways (Nitulescu et al., 2018). No reports have emerged that SC79 or similar allosteric Akt activators have been used clinically in PCOS, making this a novel application; however, the extensive research into insulin resistance and consequent metabolic dysfunction—both central aspects of PCOS—supports further investigation into this approach (Dupont & Scaramuzzi, 2016; McIlvenna, 2021).

Mechanism of Action:
Under normal physiological conditions, Akt activation is a multi-step process triggered downstream of ligand engagement of insulin and growth factor receptors. Once the receptors are activated, they recruit and phosphorylate IRS proteins that in turn activate phosphatidylinositol 3-kinase (PI3K). PI3K catalyzes the generation of the lipid second messenger phosphatidylinositol (3,4,5)-trisphosphate (PIP3), which then binds to the PH domain of Akt. This binding induces a conformational change in Akt that allows it to localize to the plasma membrane. At the membrane, Akt becomes phosphorylated at two key residues: Thr308 by phosphoinositide-dependent kinase-1 (PDK1) and Ser473 by the mTORC2 complex, leading to its full activation (Chakrabarty & Nagamani, 2008).
SC79 circumvents the need for PIP3 generation by directly binding to the PH domain of Akt. This allosteric binding mimics the conformational change that typically would be induced by PIP3 and favors Akt’s translocation and subsequent phosphorylation. Importantly, SC79 has been shown to activate all three Akt isoforms in a pan-specific manner, meaning that it can enhance the activity of Akt1, Akt2, and Akt3. This pan-isoform activity is particularly relevant given that Akt2 is known to play a significant role in insulin-stimulated glucose uptake in insulin-responsive tissues, and its activity is crucial in the ovarian context (Nitulescu et al., 2018; Jo et al., 2012). Activation of Akt by SC79 leads to the phosphorylation of downstream targets such as glycogen synthase kinase-3β (GSK-3β), which is normally inhibited once phosphorylated, and modulation of transcription factors like FOXO that are integral for cell survival and metabolic regulation (Jing et al., 2019).
PCOS is frequently characterized by defective IRS-1 phosphorylation and impaired PI3K activation, resulting in diminished endogenous Akt phosphorylation. By directly binding to and activating Akt, SC79 could theoretically bypass these defects, ensuring that downstream events—including GLUT4 translocation—proceed effectively. This would lead to improved glucose uptake, enhanced cell survival, and potentially normalized steroidogenesis in ovarian cells (Chakrabarty & Nagamani, 2008; Baptiste et al., 2010). The capacity of SC79 to “rescue” Akt signaling even when upstream signals are compromised is a noteworthy feature that has been underscored in studies involving neurons and hepatocytes, and it serves as a central pillar in the hypothesis for its use in PCOS (Jo et al., 2012; Nitulescu et al., 2018).

Expected Effect:
In the pathophysiology of PCOS, ovarian theca cells are known to exhibit insulin resistance that is partly due to impaired signaling at the level of IRS-1 and PI3K, culminating in reduced Akt phosphorylation. This defect contributes not only to metabolic dysfunction but is also implicated in abnormal steroidogenesis and hyperandrogenemia. As such, when ovarian theca cells become resistant to insulin, downstream events such as GLUT4 translocation are blunted, resulting in reduced insulin-stimulated glucose uptake and potentially exacerbating hyperinsulinemia. The working hypothesis is that SC79 will allosterically activate Akt in PCOS-derived theca cells regardless of deficient upstream signals. Through its direct binding to the Akt PH domain, SC79 is expected to robustly stimulate Akt phosphorylation at Thr308 and Ser473, acting independently of the impaired IRS-1/PI3K pathway.
With Akt activated, several beneficial downstream effects are anticipated. First, phosphorylation of Akt leads to the inactivation of GSK-3β, which would normally inhibit glycogen synthesis; its inactivation promotes glycogen storage and improves overall glucose metabolism. Second, the activation of Akt is known to initiate the phosphorylation of various substrates that facilitate GLUT4 translocation to the plasma membrane. In tissues such as skeletal muscle and adipocytes, this effect is critical for enhancing glucose uptake in response to insulin, and similar mechanisms are proposed in ovarian cells. Indeed, several studies have documented that defective Akt signaling in ovarian tissues correlates with decreased GLUT4 expression or translocation, contributing to insulin resistance (Liu et al., 2024; McIlvenna, 2021).
Moreover, enhanced Akt signaling may influence the balance of steroidogenesis. The ovarian theca cells in PCOS are known to overproduce androgens as a result of aberrant insulin signaling, and by restoring proper Akt activity, it is conceivable that abnormal androgen biosynthesis could be modulated. The normalization of Akt activity might diminish the hyperactivation of enzymes involved in androgen synthesis or correct the aberrant response to luteinizing hormone (LH) that is frequently observed in PCOS (Baptiste et al., 2010; Chakrabarty & Nagamani, 2008).
Additionally, by promoting the proper translocation of GLUT4 and improving glucose uptake, SC79 could reduce compensatory hyperinsulinemia. Elevated insulin levels are known to exacerbate ovarian dysfunction and hyperandrogenism; hence, a reduction in insulin secretion due to enhanced insulin sensitivity could confer systemic metabolic benefits. Although direct evidence of SC79’s action in ovarian theca cells is yet to be generated, studies in other cell models clearly indicate that SC79 is capable of robustly activating Akt and eliciting downstream effects that are analogous to those needed in PCOS cells (Qiu et al., 2020; Tong et al., 2022).

Overall Evaluation:
SC79 holds considerable promise as a repurposed therapeutic candidate for PCOS based on its unique mechanism of direct Akt activation and its ability to bypass upstream defects. One of the principal strengths of SC79 is its well-documented ability to bind the PH domain of Akt and promote phosphorylation at key regulatory sites, an effect that has been rigorously demonstrated in neuronal and hepatocyte models (Jo et al., 2012; Jing et al., 2019). This mechanism is particularly attractive for PCOS, in which the insulin signaling cascade is disrupted at the level of IRS-1 and PI3K, leading to deficient Akt activation. Direct activation of Akt by SC79 could restore crucial downstream processes—most notably, GLUT4 translocation and glucose uptake—even in the presence of upstream impairments. This outcome could potentially alleviate the characteristic hyperinsulinemia observed in many PCOS patients, thereby reducing its contributory effects on hyperandrogenemia and abnormal ovarian steroidogenesis (Chakrabarty & Nagamani, 2008; Baptiste et al., 2010).

The cell-permeable nature of SC79 further enhances its appeal because successful delivery into target cells is a key requirement for any candidate drug. Additionally, preclinical safety data from studies in other organ systems suggest that there exists a favorable therapeutic window for SC79 administration; these safety findings, while derived from neuronal and hepatic models, provide an initial indication that the compound could be well tolerated in vivo (Jo et al., 2012; Guan et al., 2023).

Despite these strengths, several uncertainties and potential weaknesses remain. One major challenge is the paucity of direct evidence for SC79’s effectiveness in ovarian or theca cells derived from PCOS patients. The ovarian environment in PCOS is highly complex—characterized not only by insulin resistance but also by hyperandrogenism, altered paracrine signaling among granulosa and theca cells, and abnormal extracellular matrix remodeling. Therefore, while the robust activation of Akt by SC79 in other tissues is promising, it is uncertain whether similar effects will translate seamlessly in the ovary (Liu et al., 2024; McIlvenna, 2021). Moreover, ovarian cells express a network of phosphatases and other regulatory proteins (such as PTEN) that might counterbalance the effects of sustained Akt activation. It is critical to determine whether the chronic activation of Akt could disrupt the delicate balance between cell survival and apoptosis, ultimately leading to unintended consequences such as abnormal folliculogenesis or increased risk of ovarian hyperplasia. Some studies have underscored that even when downstream nodes like Akt are activated, additional factors—such as elevated levels of inhibitory phosphatases—may modulate the final cellular response (Bellanger et al., 2014; Dupont & Scaramuzzi, 2016).

Another potential challenge relates to the specificity of SC79 in the complex microenvironment of the ovary. Although SC79 is reported to act as a pan-Akt activator, different Akt isoforms play distinct roles in various tissues. Akt2, for instance, is closely linked to glucose uptake in metabolic tissues and is expected to be beneficial when activated, whereas Akt1 and Akt3 may have divergent roles in cellular proliferation and survival. The indiscriminate activation of all isoforms might lead to off-target effects not anticipated in the simpler systems studied so far (Nitulescu et al., 2018). It will be essential to evaluate whether SC79’s activation profile in ovarian cells recapitulates the beneficial outcomes observed in cardiomyocytes or neurons without inadvertently promoting pathological proliferation or other adverse alterations.

Furthermore, the ovarian cells in PCOS are subject to multiple overlapping defects—not only in insulin signaling but also in inflammatory and oxidative stress pathways. Agents such as metformin and pioglitazone have been used clinically in PCOS with modest success, acting both on insulin sensitivity and indirectly on ovarian steroidogenesis (Baptiste et al., 2010; Wang & Li, 2023). The notion of combining SC79 with existing insulin sensitizers may be attractive if SC79 alone cannot fully restore the normal cellular phenotypes due to these additional layers of dysregulation. It may be necessary to use SC79 synergistically with other compounds to achieve the desired metabolic and endocrine improvements in PCOS (Qiu et al., 2020; Tong et al., 2022).

From a developmental perspective, the chemical simplicity and availability of SC79 (via commercial sources such as Sigma-Aldrich, catalog #S7944) are significant advantages. The ability to quickly procure and test this molecule in cellular and animal models of PCOS could accelerate the timeline for determining its efficacy and safety in this context. However, extensive preclinical studies specifically focused on ovarian cell types—ideally using cells derived from PCOS patients as well as relevant animal models that mimic the human disease—will be imperative to validate whether SC79’s direct Akt activation translates into improved GLUT4 translocation, normalized androgen production, and overall amelioration of PCOS metabolic abnormalities (Chakrabarty & Nagamani, 2008; Guan et al., 2023).

In summary, SC79 represents a highly promising candidate for repurposing in the treatment of PCOS due to its novel mechanism of directly activating Akt. By bypassing the common upstream defects in insulin receptor signaling—specifically the impaired phosphorylation of IRS-1 and subsequent PI3K activation—SC79 is expected to restore downstream metabolic processes critical for normal ovarian function. Its action is supported by extensive work in neuronal and hepatic models, where SC79 robustly promotes Akt phosphorylation, enhances cell survival, and improves metabolic outcomes. The anticipated effect in ovarian theca cells, namely the promotion of GLUT4 translocation and subsequent improvement in insulin-stimulated glucose uptake, directly addresses a core defect in the pathogenesis of PCOS (Chakrabarty & Nagamani, 2008; Baptiste et al., 2010).

Nevertheless, significant challenges remain. The current body of evidence lacks direct evaluation of SC79 in ovarian cells, and it is uncertain whether its robust activation of Akt observed in other tissues can be faithfully replicated in the unique microenvironment of the PCOS ovary. The potential for off-target effects, given the pan-Akt activation profile and the complex interplay of regulatory molecules in ovarian tissue, necessitates careful dose optimization and mechanistic studies. Additionally, the multifactorial nature of PCOS—with contributions from androgen excess, inflammation, and aberrant paracrine signaling—means that restoration of Akt activity alone might not be sufficient to fully normalize ovarian function. Combination approaches, where SC79 is used alongside established insulin sensitizers, could potentially offer additive or synergistic benefits (Dupont & Scaramuzzi, 2016; McIlvenna, 2021).

Overall, while further experimental validation in PCOS-derived ovarian theca cells and appropriate in vivo models is imperative, SC79 stands out as a conceptually innovative approach to overcome a central defect in PCOS. Its ability to activate Akt downstream of impaired insulin receptor function, coupled with prior evidence of safety and efficacy in non-ovarian tissues, provides a strong rationale for its further development. Should subsequent studies confirm that SC79 can indeed promote GLUT4 translocation, improve insulin-stimulated glucose uptake, and normalize androgen production in PCOS cells, it would represent a significant advancement in addressing the metabolic and endocrine dysregulation inherent in this syndrome (Jo et al., 2012; Nitulescu et al., 2018; Wang & Li, 2023).

In conclusion, based on the current literature, SC79 is a highly promising repurposed therapeutic candidate for PCOS. Its unique mechanism of allosteric Akt activation offers a targeted means to bypass defective upstream signaling evident in PCOS, with the potential to improve insulin sensitivity and correct associated metabolic abnormalities. Moving forward, detailed preclinical studies specifically in ovarian cell models are required to fully delineate its benefits and possible limitations. If these studies yield positive results, SC79 may well add a valuable new option in the treatment arsenal for PCOS, addressing key aspects of the syndrome that remain insufficiently managed by existing therapies.

References
Baptiste, C. G., Battista, M.-C., Trottier, A., & Baillargeon, J.-P. (2010). Insulin and hyperandrogenism in women with polycystic ovary syndrome. The Journal of Steroid Biochemistry and Molecular Biology, 122, 42–52. https://doi.org/10.1016/j.jsbmb.2009.12.010

Bellanger, S., Battista, M.-C., & Baillargeon, J.-P. (2014). Insulin resistance and lipotoxicity in PCOS: Causes and consequences. In Polycystic Ovary Syndrome (pp. 95–115). https://doi.org/10.1007/978-1-4614-8394-6_7

Chakrabarty, S., & Nagamani, M. (2008). Peripubertal hyperinsulinemia upregulates phosphatidylinositol 3-kinase/Akt pathway in rat ovaries. Reproductive Sciences, 15, 274–284. https://doi.org/10.1177/1933719108316389

Dupont, J., & Scaramuzzi, R. J. (2016). Insulin signalling and glucose transport in the ovary and ovarian function during the ovarian cycle. Biochemical Journal, 473, 1483–1501. https://doi.org/10.1042/BCJ20160124

Guan, H.-r., Li, B., Zhang, Z.-h., Wu, H.-s., He, X.-l., Dong, Y.-j., Su, J., Lv, G.-y., & Chen, S.-h. (2023). Integrated bioinformatics and network pharmacology to explore the therapeutic target and molecular mechanisms of bailing capsule on polycystic ovary syndrome. BMC Complementary Medicine and Therapies. https://doi.org/10.1186/s12906-023-04280-6

Jo, H., Mondal, S., Tan, D., Nagata, E., Takizawa, S., Sharma, A. K., Hou, Q., Shanmugasundaram, K., Prasad, A., Tung, J. K., Tejeda, A. O., Man, H., Rigby, A. C., & Luo, H. R. (2012). Small molecule-induced cytosolic activation of protein kinase Akt rescues ischemia-elicited neuronal death. Proceedings of the National Academy of Sciences, 109, 10581–10586. https://doi.org/10.1073/pnas.1202810109

Jing, Z.-T., Liu, W., Xue, C.-R., Wu, S.-X., Chen, W.-N., Lin, X.-J., & Lin, X. (2019). Akt activator SC79 protects hepatocytes from TNF-α-mediated apoptosis and alleviates D-gal/LPS-induced liver injury. American Journal of Physiology-Gastrointestinal and Liver Physiology, 316, G387–G396. https://doi.org/10.1152/ajpgi.00350.2018

Liu, J., Li, J., Wu, X., Zhang, M., Yan, G., Sun, H., & Li, D. (2024). High levels of fatty acid-binding protein 5 excessively enhances fatty acid synthesis and proliferation of granulosa cells in polycystic ovary syndrome. Journal of Ovarian Research. https://doi.org/10.1186/s13048-024-01368-6

McIlvenna, L. (2021). Polycystic ovary syndrome and insulin resistance: Dysregulation of transforming growth factor beta signalling and the effects of exercise training. Unknown Journal.

Nitulescu, G., Van De Venter, M., Nitulescu, G., Ungurianu, A., Juzenas, P., Peng, Q., Olaru, O., Grădinaru, D., Tsatsakis, A., Tsoukalas, D., Spandidos, D., & Margina, D. (2018). The Akt pathway in oncology therapy and beyond: A review. International Journal of Oncology, 53, 2319–2331. https://doi.org/10.3892/ijo.2018.4597

Qiu, Z., Dong, J., Xue, C., Li, X., Liu, K., Liu, B., Cheng, J., & Huang, F. (2020). Liuwei dihuang pills alleviate polycystic ovary syndrome with improved insulin sensitivity through PI3K/Akt signaling pathway. Journal of Ethnopharmacology, Article 111965. https://doi.org/10.1016/j.jep.2019.111965

Tong, C., Wu, Y., Zhang, L., & Yu, Y. (2022). Insulin resistance, autophagy and apoptosis in patients with polycystic ovary syndrome: Association with PI3K signaling pathway. Frontiers in Endocrinology. https://doi.org/10.3389/fendo.2022.1091147

Wang, K., & Li, Y. (2023). Signaling pathways and targeted therapeutic strategies for polycystic ovary syndrome. Frontiers in Endocrinology. https://doi.org/10.3389/fendo.2023.1191759
